Cargando…

Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use

PURPOSE: Artificial tears only provide transient relief for dry eye. To the best of our knowledge, this is the first study to objectively compare treatment with artificial tears with Keratograph 5M, which allows accurate and objective investigation of dry eye and artificial tear treatment. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Solana, Pedro, Domínguez-Serrano, Francisco de Borja, Garrido-Hermosilla, Antonio Manuel, Montero-Iruzubieta, Jesús, Fernández-Palacín, Ana, Rodríguez-de-la-Rúa-Franch, Enrique, Caro-Magdaleno, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196196/
https://www.ncbi.nlm.nih.gov/pubmed/32425501
http://dx.doi.org/10.2147/OPTH.S248949
_version_ 1783528674834776064
author Molina-Solana, Pedro
Domínguez-Serrano, Francisco de Borja
Garrido-Hermosilla, Antonio Manuel
Montero-Iruzubieta, Jesús
Fernández-Palacín, Ana
Rodríguez-de-la-Rúa-Franch, Enrique
Caro-Magdaleno, Manuel
author_facet Molina-Solana, Pedro
Domínguez-Serrano, Francisco de Borja
Garrido-Hermosilla, Antonio Manuel
Montero-Iruzubieta, Jesús
Fernández-Palacín, Ana
Rodríguez-de-la-Rúa-Franch, Enrique
Caro-Magdaleno, Manuel
author_sort Molina-Solana, Pedro
collection PubMed
description PURPOSE: Artificial tears only provide transient relief for dry eye. To the best of our knowledge, this is the first study to objectively compare treatment with artificial tears with Keratograph 5M, which allows accurate and objective investigation of dry eye and artificial tear treatment. We aimed to evaluate whether a preservative-free combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan can improve dry eye using the new topographer, Keratograph 5M. PATIENTS AND METHODS: This prospective longitudinal, single-arm interventional cohort study was performed at a tertiary referral center and involved 20 patients with dry eye (40 eyes). Preservative-free artificial tears were administered every 3 h. The participants underwent clinical and instrumental evaluations at baseline, 15, 30, 60, 90 and 120 min after instillation and 1 week and 1 month after treatment. Baseline values were considered as the controls. All patients were assessed with Keratograph 5M for non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time, conjunctival hyperemia, and tear meniscus height. Ocular surface staining with fluorescein was evaluated using the slit-lamp and fluorescein break-up time examinations, and the Ocular Surface Disease Index score was recorded for each patient. RESULTS: The signs and symptoms improved after 1 month of preservative-free 0.4% hyaluronic acid and 0.2% galactoxyloglucan treatment. There was a significant increase in the non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time at 15, 30, 60, and 90 min, and 1 week and 1 month (P < 0.05) and a decrease in hyperemia, corneal staining, and Ocular Surface Disease Index scores after 1 week and 1 month (P < 0.05). No treatment-related adverse event was observed. CONCLUSION: A combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan artificial tears seems effective for treating dry eye. Keratograph 5M can objectively detect these changes during the follow-up period.
format Online
Article
Text
id pubmed-7196196
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71961962020-05-18 Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use Molina-Solana, Pedro Domínguez-Serrano, Francisco de Borja Garrido-Hermosilla, Antonio Manuel Montero-Iruzubieta, Jesús Fernández-Palacín, Ana Rodríguez-de-la-Rúa-Franch, Enrique Caro-Magdaleno, Manuel Clin Ophthalmol Original Research PURPOSE: Artificial tears only provide transient relief for dry eye. To the best of our knowledge, this is the first study to objectively compare treatment with artificial tears with Keratograph 5M, which allows accurate and objective investigation of dry eye and artificial tear treatment. We aimed to evaluate whether a preservative-free combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan can improve dry eye using the new topographer, Keratograph 5M. PATIENTS AND METHODS: This prospective longitudinal, single-arm interventional cohort study was performed at a tertiary referral center and involved 20 patients with dry eye (40 eyes). Preservative-free artificial tears were administered every 3 h. The participants underwent clinical and instrumental evaluations at baseline, 15, 30, 60, 90 and 120 min after instillation and 1 week and 1 month after treatment. Baseline values were considered as the controls. All patients were assessed with Keratograph 5M for non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time, conjunctival hyperemia, and tear meniscus height. Ocular surface staining with fluorescein was evaluated using the slit-lamp and fluorescein break-up time examinations, and the Ocular Surface Disease Index score was recorded for each patient. RESULTS: The signs and symptoms improved after 1 month of preservative-free 0.4% hyaluronic acid and 0.2% galactoxyloglucan treatment. There was a significant increase in the non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time at 15, 30, 60, and 90 min, and 1 week and 1 month (P < 0.05) and a decrease in hyperemia, corneal staining, and Ocular Surface Disease Index scores after 1 week and 1 month (P < 0.05). No treatment-related adverse event was observed. CONCLUSION: A combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan artificial tears seems effective for treating dry eye. Keratograph 5M can objectively detect these changes during the follow-up period. Dove 2020-04-28 /pmc/articles/PMC7196196/ /pubmed/32425501 http://dx.doi.org/10.2147/OPTH.S248949 Text en © 2020 Molina-Solana et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Molina-Solana, Pedro
Domínguez-Serrano, Francisco de Borja
Garrido-Hermosilla, Antonio Manuel
Montero-Iruzubieta, Jesús
Fernández-Palacín, Ana
Rodríguez-de-la-Rúa-Franch, Enrique
Caro-Magdaleno, Manuel
Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title_full Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title_fullStr Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title_full_unstemmed Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title_short Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
title_sort improved tear film stability in patients with dry eye after hyaluronic acid and galactoxyloglucan use
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196196/
https://www.ncbi.nlm.nih.gov/pubmed/32425501
http://dx.doi.org/10.2147/OPTH.S248949
work_keys_str_mv AT molinasolanapedro improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT dominguezserranofranciscodeborja improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT garridohermosillaantoniomanuel improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT monteroiruzubietajesus improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT fernandezpalacinana improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT rodriguezdelaruafranchenrique improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse
AT caromagdalenomanuel improvedtearfilmstabilityinpatientswithdryeyeafterhyaluronicacidandgalactoxyloglucanuse